Drug Trial Radar · NCT05229562
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Feb 17, 2022
Primary completion
Sep 7, 2022
Study completion Sep 7, 2022
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Feb 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants. The main goal of the study is to compare the drug level achieved in the body, between the different ethnic groups, after single and multiple doses of BIIB122. Researchers also want to see if single and multiple doses of BIIB122 are safe and if healthy participants can tolerate given doses of BIIB122.
Conditions
- Healthy Volunteer
Interventions
BIIB122Drug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
- Time to Reach Maximum Observed Plasma Concentration (Tmax) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
- Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
- Cohorts 1,2 and 3: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB122Time frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
- Cohorts 1,2 and 3: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB122Time frame: Cohorts 1, 2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
- Cohort 4: Cmax of BIIB122 at Steady State (Cmax,ss)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
- Cohort 4: Tmax of BIIB122 at Steady State (Tmax,ss)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
- Cohort 4: AUC of BIIB122 Within a Dosing Interval at Steady State (AUCtau,ss)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
- Cohort 4: Accumulation Ratio (AR) for AUC Within a Dosing Interval (AUCtau)Time frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
- Cohort 4: AR for CmaxTime frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials, LLC
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.